Puma Biotechnology (PBYI) Expected to Announce Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Puma Biotechnology to post earnings of $0.02 per share and revenue of $44.55 million for the quarter. Puma Biotechnology has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Stock Performance

Shares of PBYI stock traded down $0.00 during trading hours on Tuesday, reaching $2.98. The stock had a trading volume of 13,059 shares, compared to its average volume of 439,133. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The firm has a 50-day simple moving average of $3.11 and a 200-day simple moving average of $3.03. The firm has a market capitalization of $147.64 million, a PE ratio of 6.21 and a beta of 1.34. Puma Biotechnology has a twelve month low of $2.23 and a twelve month high of $5.26.

Analyst Ratings Changes

PBYI has been the topic of a number of recent analyst reports. StockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Friday, February 28th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.